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Abstract
Background. Impaired renal function is evolving as
an independent marker of the risk of cardiovascular
morbidity and mortality. Little is known about the
prevalence of impaired renal function and its relation-
ship to cardiovascular risk factors in the Swiss general
population.
Methods. SAPALDIA comprises a random sample of
the Swiss population established in 1991, originally to
investigate the health effects of long-term exposure to
air pollution. Participants were reassessed in 2002/3
and blood measurements were obtained (n¼ 6317).
Renal function was estimated using the
Cockcroft–Gault equation and the modiﬁed MDRD
(four-component) equation incorporating age, race,
gender and serum creatinine level.
Results. The estimated prevalence of impaired
renal function [estimated glomerular ﬁltration rate
<60ml/min/1.73m2] differed substantially between
men and women, particularly at higher ages, and
amounted to 13% [95% conﬁdence interval (CI)
10–16%] and 36% (95% CI 32–40%) in men and
women, respectively, of 65 years or older. Smoking,
obesity, blood lipid levels, high systolic blood pressure
and hyperuricaemia were all more common in men
when compared with women. These cardiovascular risk
factors were also associated independently with creati-
nine in both women andmen.Women were less likely to
receive cardiovascular drugs, in particular angiotensin-
converting enzyme inhibitors and b-blockers, when
compared with men of the same age.
Conclusion. Moderate renal impairment seems to be
prevalent in the general population, with an apparent
excess in females which is not explained by conven-
tional cardiovascular risk factors. The unexpected
ﬁnding questions the validity of the prediction
equations, in particular in females.
Keywords: cardiovascular risk; cross-sectional survey;
diabetes; general population; prevalence; renal
impairment
Introduction
Impaired renal function is evolving as a predictor of
cardiovascular morbidity and mortality, independently
of other traditional risk factors, such as hypertension,
hypercholesterolaemia, overweight, smoking and dia-
betes [1,2], which are frequently found in patients
with renal disease [1]. Hence, in terms of planning
and targeting preventive measures for cardiovascular
disease in the general population, it is important to
estimate which proportion of the population of a
country is affected by moderate to severe renal
impairment.
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The best known large-scale population-based epide-
miological assessments that have systematically tried
to estimate the prevalence of cardiovascular risk
factors and impaired renal function are PREVEND
in The Netherlands [3] and NHANES III [Third
National Health and Nutrition Examination Survey
(1988–1994)] in the USA [4]. However, in most
European populations, the prevalence of moderate to
severe renal impairment is unknown.
The Swiss Cohort Study on Air Pollution and Lung
Diseases in Adults (SAPALDIA) enrolled a random
population sample at the baseline assessment in 1991
and measured a range of cardiovascular blood
markers at the ﬁrst follow-up assessment of the
cohort in 2002. We therefore had the opportunity to
obtain a crude estimate of the prevalence of moderate
to severe renal impairment. Further, we investigated
the association between renal impairment and cardio-
vascular risk factors in the Swiss population. However,
in this cross-sectional assessment, we are unable to
hypothesize on the direction of the effect between
cardiovascular risk factors and serum creatinine
measurements.
Subjects and methods
SAPALDIA 2
The SAPALDIA was originally designed to investigate
the effects of air pollutants on respiratory health (including
lung function, development of symptoms and disease) in a
random sample of the adult population of Switzerland [5,6].
The original study consisted of 9651 adults as described
elsewhere [5]. The extensive health examinations included a
detailed assessment of personal risk factors of respiratory
health over the course of 1 year (1991). Of the surviving
9368 participants, 93% (n¼ 8715) could be traced between
2001 and 2003, and were re-contacted for SAPALDIA 2 [6].
Both surveys were an extensive version of the European
respiratory health survey [7] and comprised interviews and
examinations by trained ﬁeldworkers. In the second survey,
there was additionally a collection of blood specimens and
blood pressure measurements [6].
Ethical approval for SAPALDIA 2 was given by the
central ethics committee of the Swiss Academy of Medical
Sciences and the Cantonal Ethics Committees for each of the
eight examination areas. The consent information provided to
participants described the health examination, the blood
measurements and information on data protection. Subjects
could either give global consent (for all health examinations)
or agree to each investigation separately.
The detailed assessment of the representativeness of
this cross-sectional assessment of the original cohort can be
found in Ackermann-Liebrich et al. [6]. Brieﬂy, subjects who
agreed to have their blood analysed were similar to those
who did not participate in the follow-up study except that
a considerable proportion of smokers (28%) had quit
smoking. However, the overall distributions of age, sex and
body mass index (BMI) were still comparable with those of
the general Swiss population, including weight gain over
10 years.
Interviews, blood pressure measurements and
serum creatinine measurements
The interview included various questions including smoking
habits, presence of diabetes and physical activity. Details of
present and past medication use were obtained for all
participants and were veriﬁed by checking the actual
prescription drug packets.
Systolic and diastolic blood pressures were measured after
the participant had sat quietly for at least 10min. Pressures
were measured twice with an interval of at least 3min using an
automatic OMRON 705 CP (Tokyo, Japan). The results
reported here derive from the average of both measurements.
Weight and height were measured in a standardized fashion.
Blood samples were taken from all 6327 subjects who had
consented to the general blood marker analyses. Blood
samples were processed and stored in a standardized fashion
according to the SAPALDIA protocol [6]. All laboratory
measurements were carried out in the laboratory of the
University Hospital Zurich on batches of on average 100
samples. Serum creatinine was measured using the Jaffe´
reaction (Roche) and calibrated to the Roche enzymatic gold
standard reference. This calibration will yield slightly lower
serum creatinine measurements than the Cleveland Clinic
Jaffe´ reaction [8].
Estimation of renal function and markers of the
metabolic syndrome complex
All the following analyses were restricted to the sample with
available serum creatinine measurements (n¼ 6317). Renal
function was estimated using the modiﬁed MDRD (four-
component) equation incorporating age, sex, serum creatinine
level and an adjustment for African descent. The formula
reads:
eGFR ðMDRDÞ
¼ 186 ½ðserum creatinine in mg=dlÞ ð1:154Þ
 ½age ð0:203Þ
multiplied by a correction factor of 0.742 if the participant
was female [9,10]. This was a Caucasian population. Because
of the enzymatic calibration method of measuring serum
creatinine, the estimated glomerular ﬁltration rate (eGFR)
using the MDRD equation is 5% higher than it should be
based on the MDRD study [8]. Hence, we might slightly
overestimate renal function throughout our study.
An alternative estimator of renal function was the
Cockcroft–Gault equation, calculated as:
eGFR ðCockcroftGaultÞ
¼ ½140 age ðyearsÞ  weight ðkgÞ
 1:23=serum creatinine ðmmol=lÞ
multiplied by a correction factor of 0.85 if the participant
was female [11,12]. A correction for body surface area (BSA)
was carried out by correcting the eGFR (Cockcroft–Gault)
according to Du Bois [13] where BSA¼weight (kg)
0.425 height (m) 0.725 0.202.
These measures of eGFR were categorized according to
NKF KDOQI into below and above stage 3 renal disease
(<60ml/min/1.73m2) [12].
A third, very crude estimator of renal function was 100/
[serum creatinine (mg/dl)] [12]. Of note is that both equations
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above contain an inverse of serum creatinine, so that this
estimator is approximately proportional to both MDRD
and Cockcroft–Gault eGFRs.
Variables belonging to the metabolic syndrome complex
[triglycerides and high-density lipoprotein (HDL) cholesterol]
were categorized according to ATP III guidelines, where
applicable [14]. Since blood glucose and blood lipids were not
always measured after 12 h fasting, we decided not to apply
the ATP III categorization to blood glucose and low-density
lipoprotein (LDL) cholesterol. A haemoglobin A1c measure-
ment was obtained only in participants with blood glucose
values >6.1mmol/l. Age groups were categorized for tabula-
tion into those <55, 55–65 and >65 years of age. Medication
history was coded in a standardized fashion according to
ATC codes [15]. In particular, we used the ATC deﬁnition for
cardiovascular drugs (antihypertensive medication as well as
lipid-lowering therapy) and its categorization for diuretics
and angiotensin-converting enzyme (ACE) inhibitors/
angiotensin II receptor blockers (ARBs). Medication history
of drugs was used as an indirect marker of preceding or
underlying medical, in particular cardiovascular, problems.
Statistical analysis
We performed simple tabulations of proportions according to
gender and age. For initial baseline analyses, Kruskal–Wallis
tests and F tests as well as 2 tests or Fisher’s exact tests were
carried out to determine the signiﬁcance, when necessary.
In models using eGFR based on Cockcroft–Gault and
MDRD equations, associations between age, sex and eGFR
will exist by default, which in the presence of random error
might distort the ﬁndings [16]. Therefore, we ran two different
linear regression models with two different outcomes. The
ﬁrst used eGFRwas based on theMDRD equation and it was
therefore easier to interpret the outcome variable. The second
used the estimator based on the inverse of serum creatinine as
a conceptual crude measurement of renal function. In
contrast to the raw serum creatinine measurements, both
the inverse of serum creatinine and the MDRD eGFR were
approximately normally distributed.
Age at the time of the blood collection, BMI, C-reactive
protein (CRP) and blood pressure measurements were
entered as continuous variables, centred on norm values
(i.e. CRP¼ 0, systolic blood pressure 125mmHg, diastolic
blood pressure 80mmHg) or their mean (i.e. age).
Cholesterol, HDL and triglyceride measurements were
centred on their mean. LDL was omitted because it had
been derived from the latter measurements by calculation.
The number of ever prescribed drugs was entered as a score
variable, and physical activity as a categorical variable. The
medication categories cardiovascular drugs, ACE inhibitors/
ARBs and diuretics were each coded as binary variables.
Smoking habits in 2001/2 at the time of blood measurements
were categorized as current, past and non-smokers. The
variable diabetes was binary, containing information on self-
reported presence of the disease. Because of several non-linear
associations, polynomial regression analysis was used to ﬁnd
the best order of transformation of exposure variables. In the
case of BMI and age, this was a quadratic association.
We used the transformed exposure variables and addition-
ally entered variables in a stepwise fashion into our linear
regression model while examining the confounding effects
between different variables during the model building
process. A ﬁnal model tested speciﬁcally for interactions
between predicting variables and gender as well as diabetes
using Wald tests. The gender-speciﬁc interactions were
signiﬁcant for both MDRD-based models as well as the
inverse of serum creatinine (for both outcomes: P<0.001
in the overall test of all interaction terms). The interaction
terms with diabetes were not signiﬁcant either for the MDRD
or for the inverse of serum creatinine (overall Wald tests for
interaction: P¼ 0.102 and P¼ 0.101, respectively). Variables,
unless they were a priori confounders such as diabetes or
age, were omitted from the ﬁnal model if they did not
reach statistical signiﬁcance (P¼ 0.05) in at least one
gender group. For easier interpretability, results are reported
using the categorical associations for age and BMI
using the gender-speciﬁc models. Investigation of outliers
revealed those individuals with high CRP and urate;
however, these had no inﬂuence on the size or direction of
the ﬁnal results. Analyses were carried out with Stata
version 8 [17].
Results
The characteristics of participants by gender and age
are displayed in Table 1. On average and compared
with women, men had higher systolic and diastolic
blood pressures, triglycerides, glucose, urate and serum
creatinine as well as lower levels of HDL cholesterol.
BMIs and total cholesterol levels were higher for men
than for women, except in the age group above
65 years, with women having a tendency to obesity.
Interestingly, CRP levels were higher in women
compared with men. When stratiﬁed according to
ATC III recommendations for the prevention of
cardiovascular disease, men presented more fre-
quently than women with hypertriglyceridaemia,
low HDL cholesterol, smoking and diabetes mellitus.
Comparison of physical activity patterns between the
sexes revealed more physical activity leading to sweat-
ing in men compared with women across all ages.
Women were more likely to have taken at least one
medication at ages above 55 years. However, the main
bulk of the ever prescribed medication were cardio-
vascular drugs, particularly in men, increasing across
age groups. ACE inhibitors and ARBs, as well as
b-blockers, were prescribed more often to men than to
women. In summary, the cardiovascular proﬁle was
more favourable for women than for men, except for
the presence of higher CRP levels and a higher
prevalence of obesity in the older age groups.
Mean creatinine was higher for men than for women
and increased slightly with age (Table 1, Figure 1).
Nevertheless, in all age strata, the median eGFR was
lower in women than in men, especially in the older age
groups. Both Figures 1B and 2A show that the major
bulk of the distributions of eGFR <60ml/min/1.73m2
within each age and sex category lie between 30 and
60ml/min/1.73m2, with the boxes and capped lines not
extending below the 30ml/min/1.73m2 line and the
proportion of individuals with an eGFR <45ml/min/
1.73m2 being much smaller. This is especially the case
for women, whereas severe outliers occurred more
often for men.
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Table 1. Characteristics of participants by gender and age group
Characteristics
(unit)
Men Women P-value
for men
Total
(n¼ 3100)
<55 years
(n¼ 1751)
55–65 years
(n¼ 901)
>65 years
(n¼ 448)
Total
(n¼ 3217)
<55 years
(n¼ 1813)
55–65 years
(n¼ 877)
>65 years
(n¼ 527)
vs women
by age
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age (years) 51.8 11.4 43.3 7.4 59.7 2.8 68.6 2.2 52.5 11.4 44.1 7.2 59.8 2.9 68.8 2.2 0.0629
SBP (mmHg) 132.3 17.8 127.7 14.8 136.4 18.7 141.3 20.5 120.8 19.1 114.0 15.8 126.4 18.0 135.9 20.0 <0.001
DBP (mmHg) 82.5 10.7 81.2 10.3 84.5 10.8 83.3 11.2 76.8 10.4 74.7 10.1 79.4h 10.2 80.4 10.2 <0.001
Weight (kg) 81.8 12.6 81.4 12.9 82.7 12.1 81.9 12.9 66.8 12.9 65.6 13.0 68.1 13.0 69.4 13.2 0.001
BMI (kg/m2) 26.6 3.8 26.0 3.8 27.3 3.6 27.6 3.7 25.2 4.8 24.3 4.7 26.0 4.7 27.1 4.9 <0.001
Total cholesterol (mmol/l) 6 1.1 6.0 1.1 6.1 1.1 6.0 1.1 6 1.1 5.8 1.1 6.4 1.1 6.5 1.1 <0.001
HDL-cholesterol (mmol/l) 1.3 0.4 1.3 0.4 1.3 0.4 1.3 0.3 1.7 0.4 1.7 0.4 1.7 0.5 1.6 (0.5) 0.027
Triglycerides (mmol/l)* 1.8 1.2–2.7 1.6 1.1–2.5 1.9 1.3–2.9 1.9 1.4–2.8 1.3 0.9–1.9 1.1 0.8–1.6 1.5 1.1–2.2 1.7 1.2–2.4 <0.001
BG (mmol/l) 5.8 1.8 5.5 1.2 6.1 2.5 6.1 1.8 5.4 1.2 5.2 1.1 5.6 1.2 5.8 1.5 <0.001
Creatinine (mmol/l)* 94 87–101 93 87–100 94 87–103 96 88–104 81 75–87 80 74–86 81 76–88 83 76–90 <0.001
eGFR (ml/min/1.73m2) 78.9 11.5 82.4 10.4 75.6 10.8 72.3 12.2 69.3 10.4 72.6 9.9 66.2 8.8 63.0 9.9 <0.001
Urate (mmol/l) 363 8.9 355.9 75.8 370.1 81.2 376.0 83.1 269.7 68.3 251.8 58.7 282.9 67.4 309.5 77.9 <0.001
hsCRP (mg/l)* 1 (0.5–2.1) 0.8 0.4–1.7 1.2 0.6–2.4 1.4 0.7–3.1 1.1 0.5–2.6 0.8 0.4–2.0 1.4 0.7–3.0 1.8 0.9–3.9 <0.001
Median no. of medications used (IQR)* 0 0–1 0 0–0 0 0–2 1 0–3 0 0–2 0 0–1 1 0–3 1 0–3 <0.001
n % n % n % n % n % n % n % n %
Obesea 501 16.2 217 12.4 183 20.3 101 22.6 490 15.3 189 10.4 169 19.4 132 25.2 0.1538
Low HDL cholesterolb 543 17.5 302 17.3 170 18.9 71 15.9 625 19.4 310 17.1 193 22.0 122 23.2 0.03
Hypertriglyceridaemiac 1636 52.8 850 48.5 523 58.1 263 58.7 1044 32.5 419 23.1 367 41.9 258 49.0 <0.001
High blood pressured 1482 49.2 686 40.2 524 59.8 272 63.1 906 29.3 302 17.2 335 39.6 269 54.2 <0.001
Active smokerse 841 27.2 529 30.9 227 25.2 85 19.0 722 22.5 497 27.5 174 19.9 51 9.7 <0.001
Diabetes 144 4.7 28 1.6 75 8.3 41 9.2 72 2.2 14 0.8 26 3.0 32 6.1 <0.001
HbA1c >6.5% 146 4.7 32 1.8 71 7.9 43 9.6 75 2.3 19 1.1 18 2.1 38 7.2 0.007
Physical activity leading
to sweatingf
<0.001
Never 731 23.9 324 18.8 253 28.3 154 34.8 1080 34.1 501 28.1 330 38.3 249 47.8
Once per week 1159 37.9 672 39.0 337 37.7 150 33.9 1129 35.7 690 38.7 282 32.7 157 30.1
Several times per week 1170 38.2 727 42.2 305 34.1 138 31.2 955 30.2 590 33.1 250 29.0 115 22.1
At least one medication
ever taken
1323 42.7 487 27.8 516 57.3 320 71.4 1736 54.0 721 39.8 594 67.7 421 79.9 <0.001
% cardiovascular medicationsg 737 55.7 177 36.3 335 64.9 225 70.3 649 37.4 159 22.1 242 40.7 248 58.9 <0.001
% ACE inhibitors/ARBsg 314 23.7 65 13.4 147 28.5 102 31.9 253 14.6 50 6.9 81 13.6 122 29.0 <0.001
% b-Blockersg 297 22.5 65 13.4 144 27.9 88 27.5 249 14.3 47 6.5 101 17.0 101 24.0 <0.001
% Diureticsg 67 5.1 9 1.9 29 5.6 29 9.1 100 5.8 18 2.5 32 5.4 50 11.9 0.303
*Median and interquartile range are given instead of mean (SD); comparisons were carried out using the Kruskal–Wallis test.
SBP, systolic blood pressure; DBP, diastolic blood pressure (212 blood pressure measurements missing); BMI, body mass index (20 missing); BG, blood glucose; HbA1c, haemoglobin A1c
(measured on 1230 subjects with an elevated blood glucose); eGFR, estimated glomerular ﬁltration rate (measured by the MDRD equation; hsCRP, high sensitive C-reactive protein; IQR,
interquartile range; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
aBMI >30kg/m2.
bHDL <1.0mmo/l in men and <1.3mmol/l in women.
cTriglycerides 1.7mmol/l.
dBlood pressure 135/85.
eNine values missing.
fNinety-three values missing.
gPercentage of medication categories calculated for those who ever took at least one medication.
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Overall, women were found to present more fre-
quently than men with stage 3 renal impairment
according to NKF KDOQI, i.e. with an eGFR of
<60ml/min/1.73m2 (see Figure 2). This was observed
independently of whether the MDRD or the
Cockcroft–Gault formula was used (Figures 1 and 2).
Using the MDRD equation, we estimated the following
prevalences for men and women, respectively: at ages
below 55 years, 1.1% [95% conﬁdence interval (CI)
0.6–1.6%] and 7.9% (95% CI 6.7–9.2%); at ages
between 55 and 65 years, 7.1% (95% CI: 5.4–8.8%)
and 23.5% (95% CI 20.7–26.3%); and at ages above
65 years, 12.9% (95% CI 9.8–16.1%) and 35.9%
(95% CI 31.8–40.0%).
In Figure 2, we see that the black columns for the
Cockcroft–Gault are higher than the white columns for
the MDRD-estimated proportions; fewer individuals
presented with impaired renal function if estimated by
MDRD as compared with Cockcroft–Gault. It follows
that distributions of prediction from the two formulae
only partially overlapped. In Figure 2B, the light grey
columns show the proportions of patients categorized
as <60ml/min/1.73m2 by either of the equations, while
the dark grey columns show the proportions of those
<60ml/min/1.73m2 according to both equations at the
same time. The four patients who were dialysis
dependent were appropriately categorized by all pre-
diction formulae correctly into the low eGFR category.
However, according to Figure 2B, divergences
between women and men in terms of their prevalence
of eGFR <60ml/min/1.73m2 in age groups above 40
years is not explained by discrepancies betweenMDRD
and Cockcroft–Gault equations. We still observe a 2- to
4-fold increase of estimated moderately impaired renal
function in women as compared with men.
In a next step, relationships between cardiovascular
risk factors and creatinine measurements were investi-
gated. The results of the ﬁtted associations are given in
Tables 2 and 3. We used both MDRD and the inverse
of creatinine estimator as a conceptual crude measure-
ment of renal function (for details, see Subjects and
methods). Because for both outcomes overall interac-
tions between predictors and gender were found, we
present the absolute effects of predictors separately
using gender-speciﬁc models. Because diabetic patients
have a substantially different cardiovascular risk
proﬁle, diabetes was included as a predictor, without
however reaching statistical signiﬁcance in any of the
models. Physical activity was retained in the model,
possibly because of its association with muscle mass
which is only inappropriately captured by BMI. Older
individuals had lower eGFR and inverse serum
creatinine values corresponding to more impaired
renal function. The effect of age group on inverse
serum creatinine was ﬂatter than for the MDRD-based
regressions because the inverse of serum creatinine
incorporates the effect of age both on muscle and on
kidney function and creatinine handling. For men,
there was a U-shaped relationship between eGFR and
BMI, while for women there was a more J-shaped
association. There was a positive signiﬁcant association
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Fig. 1. (A) Box-plot of creatinine ( y-axis) stratiﬁed by gender and
age groups (in years) (x-axis). The four male dialysis patients with
values of creatinine >400mmol/l are omitted in order to display the
rest of the distribution on a larger scale. Horizontal lines indicate
abnormally low or high creatinine values (57 and 104mmol/l). Age
category 20 denotes individuals from 20 up to 29 years, age
category 30 those aged 30–39, etc., up to age category 70 which
encompasses those aged 70 and above. (B) Box-plot of MDRD and
Cockcroft–Gault eGFR (y-axis) stratiﬁed by gender and age groups
(in years) (x-axis). Horizontal lines indicate NKF KDOQI
categories of <60ml/min/1.73m2 (stage 3, moderately impaired
GFR), <30ml/min/1.73m2 (stage 4, severe impairment) and
<15ml/min/1.73m2 (stage 5, kidney failure). (C) Conceptual
display of a histogram and a corresponding box-plot to facilitate
interpretation of (A) and (B). Boxes represent 25–75 percentiles of
the distribution, with medians denoted by the middle lines within
the boxes. Upper and lower adjacent values (2.5–97.5 percentiles)
are indicated with capped lines; outside values are denoted by
circles or squares.
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with current smoking, a negative relationship with
serum lipid markers, as well as a negative relationship
with serum urate levels. Serum urate levels, diuretic
medication and the number of substances taken were
confounding each other—the most parsimonious
model was the one with serum urate and number of
substances ever taken.
A subgroup analysis in those individuals who took at
least one medication was conducted to evaluate the
effect of the medication subgroup. In men, none of the
subgroups had a signiﬁcant impact on renal impairment
above the information carried in the sum total of
medications ever taken. In women, there was some
confounding between cardiovascular medication and
sum total of medications taken on inverse creatinine,
with a borderline effect for ACE inhibitors (P¼ 0.062),
and a signiﬁcant effect for diuretics in the MDRD
model (P¼ 0.012). However, in the full sample, there
was overall only borderline evidence for a differential
relationship between the sexes by type of medication if
adjusted for serum urate (inverse creatinine, P-values
for interaction >0.1; MDRD, P-value for inter-
action¼ 0.082 for diuretics; other P-values for interac-
tion >0.1; results not shown).
It is of note that the HDL level did not reach
statistical signiﬁcance in either sex and therefore was
excluded from the model. Isolated systolic blood
pressure increases were signiﬁcantly associated with
eGFRmeasures. Diastolic blood pressure did not reach
the level of statistical signiﬁcance and was omitted
from the model. The relationship between CRP and
renal function differed by sex (P-value for inter-
action¼ 0.001), with women having a positive associa-
tion, and men a negative association. The associations
remained of similar size and signiﬁcance when
outliers, such as high CRP levels, were excluded from
the model.
Discussion
This is to our knowledge the ﬁrst population-based
cross-sectional assessment of the prevalence of renal
impairment and cardiovascular risk factors in
Switzerland. In general, the cardiovascular risk proﬁle
seemed more favourable for women than for men.
However, in the Swiss population, moderate to severe
renal impairment, as deﬁned by NKF KDOQI, seemed
to be more common in women, particularly in the older
age groups.
NKF KDOQI guidelines recommend the use of
serum creatinine-based predictions of eGFR, prefer-
ably MDRD and Cockcroft–Gault equations, to target
speciﬁcally patients with renal impairment with an
eGFR <60ml/min/1.73m2 for further cardiovascular
assessment [12], and NHANES III has usedMDRD for
estimation of the prevalence of renal impairment in the
general population [4]. Because of the enzymatic
calibration of the serum creatinine assays, we might
have overestimated the eGFR by 5% using the
MDRD equation [8]. Because this is an assessment of
the general population, the measurement error intro-
duced by non-creatinine chromogen substances can
be believed to be fairly low and to not bias our results.
This study was limited in not having urinary measure-
ments, and the presence of proteinuria could have
been an important indicator for the effective presence
of an active kidney disease. However, according to
the KDOQI guidelines, the availability of additional
spot urine measurements to quantify proteinuria/
microalbuminuria is particularly important when
classifying subjects in stages 1 and 2 as having chronic
kidney disease [12]. This study focused on more severe
impairment.
The prevalence of moderate to severe renal disease
might be estimated from creatinine measurements
by general practitioners’ or hospital laboratories.
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Fig. 2. (A) Prevalence (y-axis) of eGFR <60ml/min/1.73m2 and
<45ml/min/1.73m2, stratiﬁed by gender and age groups (in years)
(x-axis). Tall white boxes represent the proportion who were
estimated to be <60ml/min/1.73m2, and the shorter boxes those
<45ml/min/1.73m2 according to MDRD; tall black boxes show
those proportions<60ml/min/1.73m2 according to the body surface-
adjusted Cockcroft–Gault equation, and the shorter ones those
<45ml/min/1.73m2. Age category 20 denotes individuals from 20 up
to 29 years, age category 30 those aged 30–39, etc., up to age category
70 which encompasses those aged 70 and above. (B) Comparison of
formulae estimating the prevalence ( y-axis) of eGFR <60ml/min/
1.73m2, stratiﬁed by gender and age groups (in years) (x-axis). White
boxes represent proportions according to MDRD, black boxes those
according to the body surface-adjusted Cockcroft–Gault equation
(equivalent to the tall boxes in A). Light grey boxes display the
proportions within each age/gender stratumwho, according to at least
one of the formulae, would be have moderate renal impairment, dark
grey boxes those whowould be<60ml/min/1.73m2 according to both
equations at the same time.
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Table 3. Final model for the relationship between inverse creatinine and cardiovascular markers in men and women
Unit Men Women
Estimate 95% CI P-value Estimate 95% CI P-value
Baseline* 100/creatinine (dl/mg) 95.12 93.37 to 96.87 <0.001 104.89 102.72 to 107.07 <0.001
Effect of age* 40–49 years 1.78 0.59 to 2.98 0.003 0.24 1.15 to 1.63 0.735
50–59 years 1.31 0.13 to 2.50 0.029 0.13 1.32 to 1.58 0.861
60–69 years 0.69 0.62 to 2.01 0.302 1.26 2.91 to 0.38 0.132
70 years 1.69 3.82 to 0.43 0.118 1.24 3.64 to 1.16 0.311
BMI <20kg/m2 1.09 1.81 to 3.99 0.46 0.36 1.87 to 1.15 0.64
25–29.9 kg/m2 0.55 1.44 to 0.35 0.233 0.31 0.78 to 1.39 0.58
30–34.9 kg/m2 0.93 0.42 to 2.27 0.178 3.00 1.41 to 4.58 <0.001
35 kg/m2 3.62 1.22 to 6.03 0.003 4.78 2.28 to 7.27 <0.001
Smoking Former 1.43 0.50 to 2.37 0.003 0.37 0.70 to 1.43 0.5
Current 3.75 2.78 to 4.73 <0.001 2.62 1.51 to 3.73 <0.001
Presence of diabetes vs absent 1.18 0.77 to 3.13 0.235 0.82 2.23 to 3.86 0.6
CRP 1mg/l increase 0.07 0.15 to 0.02 0.119 0.28 0.16 to 0.40 <0.001
Triglycerides 1mmol/l increase 0.60 0.89 to 0.31 <0.001 0.09 0.62 to 0.44 0.747
Cholesterol 1mmol/l increase 0.60 0.98 to 0.23 0.001 0.88 1.31 to 0.45 <0.001
Blood pressure Systolic 10mmHg increase 0.08 0.16 to 0.32 0.517 0.41 0.14 to 0.68 0.003
Urate levels 1mmol/l increase 0.03 0.04 to 0.03 <0.001 0.07 0.07 to 0.06 <0.001
Medication Per substance increase 0.43 0.69 to 0.17 0.001 0.34 0.59 to 0.08 0.011
Physical activity leading
to sweating
Once/week vs never 1.14 2.20 to 0.08 0.035 1.15 2.24 to 0.05 0.041
Several times/week vs never 1.53 2.62 to 0.44 0.006 1.10 2.28 to 0.08 0.067
A baseline individual for both men and women is a person with BMI between 20 and 24.9 kg/m2, an age of 30–39 years, mean cholesterol,
HDL and triglyceride levels, CRP of zero, non-smoking and non-diabetic and with a blood pressure of 125/80mmHg, and a urate
<350 mmol/l.
*Adjusted for all other variables displayed and area of residence.
Table 2. Final model for the relationship between MDRD and cardiovascular markers in men and women
Unit Men Women
Estimate 95% CI P-value Estimate 95% CI P-value
Baseline* ml/min/1.73m2 85.64 83.97 to 87.31 <0.001 71.19 69.60 to 72.78 <0.001
Effect of age* 40–49 years 2.59 3.72 to 1.45 <0.001 3.69 4.71 to 2.68 <0.001
50–59 years 6.27 7.40 to 5.14 <0.001 6.47 7.53 to 5.41 <0.001
60–69 years 9.17 10.42 to 7.92 <0.001 9.57 10.77 to 8.36 <0.001
70 years 12.79 14.82 to 10.77 <0.001 10.67 12.42 to 8.91 <0.001
BMI <20kg/m2 1.06 1.71 to 3.83 0.452 0.36 1.46 to 0.75 0.526
25–29.9 kg/m2 0.62 1.48 to 0.23 0.155 0.23 0.57 to 1.02 0.575
30–34.9 kg/m2 0.77 0.51 to 2.05 0.24 2.19 1.03 to 3.35 <0.001
35 kg/m2 3.26 0.96 to 5.56 0.005 3.59 1.77 to 5.42 <0.001
Smoking Former 1.23 0.34 to 2.12 0.007 0.23 0.54 to 1.01 0.554
Current 3.57 2.65 to 4.50 <0.001 1.91 1.10 to 2.73 <0.001
Presence of diabetes vs absent 1.07 0.79 to 2.92 0.261 0.48 1.74 to 2.71 0.67
CRP 1mg/l increase 0.06 0.14 to 0.02 0.162 0.21 0.12 to 0.30 <0.001
Triglycerides 1mmol/l increase 0.56 0.83 to 0.28 <0.001 0.02 0.41 to 0.36 0.911
Cholesterol 1mmol/l increase 0.63 0.98 to 0.27 0.001 0.71 1.02 to 0.39 <0.001
Blood pressure Systolic 10mmHg increase 0.05 0.18 to 0.28 0.655 0.23 0.04 to 0.43 0.02
Urate levels 1mmol/l increase 0.03 0.04 to 0.03 <0.001 0.05 0.05 to 0.04 <0.001
Medication per substance increase 0.42 0.67 to 0.18 0.001 0.27 0.45 to 0.08 0.006
Physical activity leading
to sweating
Once/week vs never 1.18 2.19 to 0.17 0.022 0.77 1.57 to 0.03 0.06
Several times/week vs never 1.43 2.47 to 0.39 0.007 0.74 1.60 to 0.12 0.092
A baseline individual for both men and women is a person with BMI between 20 and 24.9 kg/m2, an age of 30–39 years, mean cholesterol,
HDL and triglyceride levels, CRP of zero, non-smoking and non-diabetic and with a blood pressure of 125/80mmHg, and a urate
<350 mmol/l.
*Adjusted for all other variables displayed and area of residence.
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Apart from the problem of standardization of serum
creatinine measurements across different laboratories,
such data only include patients who need a general
practitioner or need to attend hospital, and therefore
may represent a subgroup with a greater risk for renal
disease than the general population and overestimate
the prevalence of renal disease. Our study is examining
a healthy general population. However, we cannot rule
out that some of those who did not agree to assessment
(n¼ 2388, 27.4%) were systematically more ill than
those who did agree to the blood measurements. There
was a slightly greater proportion of women and ex-
smokers in our sample, which highlights a possible
participation bias. Furthermore, the blood measure-
ments were obtained 10 years after the original
recruitment of participants into the study, with 283
having died.
Despite these shortcomings of our data, there are
several reasons to take our ﬁndings seriously. First of
all, the use of sex- and age-stratiﬁed prevalence
estimates takes age and sex imbalances into account.
Secondly, the prevalence obtained for smoking,
obesity and indicators of the metabolic syndrome
associated with cardiovascular disease was in accor-
dance with other surveys of cardiovascular risk factors
in the general population across Europe and as
observed in PREVEND [3,4,18–20]. The associations
between cardiovascular risk factors and serum creati-
nine were in line with PREVEND, with smoking and
high systolic blood pressure being more strongly related
to microalbuminuria in the general population whereas
their effect went in both directions for eGFR [3]. This
would ﬁt our ﬁndings of an increase in eGFR possibly
related to hyperﬁltration due to smoking and high
systolic blood pressure [21]. Elevated CRP levels are
known to be associated both with hyperﬁltration and
with diminished ﬁltration depending on BMI. CRP also
seems to modify the relationship between microalbu-
minuria and hypertension [22]. We are unable to
investigate this further.
Lastly, the prevalence of renal impairment in men
was similar to that observed in NHANES III and
PREVEND [3,4,22]. However, we observed an excep-
tionally high prevalence for moderate to severe renal
impairment estimates in women.
A survivor bias in favour of women is unlikely to
explain the large differences between sexes, particularly
for age groups 50–69, because over a period of 11 years
only 283 had died. Even if these included all males with
renal impairment, these are not sufﬁcient to ﬁll the gap
in observed prevalence of renal impairment between
men and women.
It is very unlikely that the calibration explains the
major sex differences found in this study, because all
batches were analysed together. Several patients, and
particularly older female patients, could just have had
some functional reversible kidney impairment due,
for example, to diuretic intake, a voluntary ﬂuid
restriction before the examination or a regular intake
of analgesics. In both women and men, creatinine was
associated with medication history, being an indirect
marker of co-morbidities, as described previously [3].
Men had more cardiovascular drug prescriptions,
including b-blockers and ACE inhibitors/ARBs.
This is in line with the higher prevalence of hyper-
tension and other risk factors in men compared with
women. We found that medication had a larger
absolute effect on eGFR in men than in women, while
for serum urate the effects were comparable. Hence,
it is unlikely that functional reversible renal impair-
ment explains the differences in prevalence of renal
impairment.
It remains a possibility that the correction factors for
female sex in both MDRD and Cockcroft–Gault
formulae are incorrect. This might explain to
some extent the substantial differences in estimated
renal function between women and men. The
Cockcroft–Gault equation was developed to estimate
creatinine clearance in young healthy men and is known
to overestimate GFRs when renal function is severely
impaired [11]. On the other hand, MDRD is inaccurate
in healthy slim young individuals. However, the
performance of MDRD increases if GFR is <60ml/
min/1.73m2 and at older ages [4,9,10,23,24], and recent
European validation studies support some but not such
large errors in correction factors between men and
women [16,23]. The slightly different relationships of
cardiovascular risk factors with both inverse creatinine
and eGFR could indicate that post-menopausal
women might even have a different pattern of declining
renal function with age than captured by those
formulae.
Many recent estimates obtained by epidemiological
assessments of the cardiovascular risk associated with
renal function rely on estimations based on MDRD or
Cockcroft–Gault [1]. Therefore, even if these formulae
are not a reﬂection of the eGFR itself, these are still
transformations of serum creatinine that—even for
eGFRs between 30 and 60ml/min/1.73m2—seem to be
highly associated with cardiovascular risk in both sexes.
Hence, despite the problems mentioned, our estimates
seem robust, in view of the overestimation of eGFR
together with a possible survivor and responder bias,
even slightly optimistic picture of the current situation
of cardiovascular risk factors in Switzerland, with
women at older ages possibly at higher risk for
cardiovascular disease than estimated previously by
conventional risk factors.
Potential factors that could be ameliorated in the
older age groups are more physical activity and weight
reduction. Smoking, in particular in the young groups,
is a further problem, and is currently targeted by the
Swiss Health Authorities.
In conclusion, cardiovascular risk and impaired renal
function might be underappreciated in women in
Switzerland. However, there remains some doubt
about the validity of prediction equations, in particular
in females. In view of the ageing population and
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because of the estimated high prevalence of moderate to
severe renal impairment in the general Swiss popula-
tion, the ﬁndings of this cross-sectional study are
particularly important and require further detailed
assessments.
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